ClinicalTrials.gg
Not yet recruitingNCT06952023PEACE-AFUpdated Apr 30, 2025

PFA-based Bi-atrial Maze-like Catheter Ablation for PeAF

An interventional study of Modified Maze ablation with PFA and PVI only with PFA in Atrial Fibrillation and Persistent Atrial Fibrillation, sponsored by The First Affiliated Hospital of Dalian Medical University. Not yet recruiting at 3 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by The First Affiliated Hospital of Dalian Medical University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

In radiofrequency (RF) ablation of persistent atrial fibrillation (PeAF), the additional linear ablation beyond pulmonary vein isolation (PVI) does not yield an reduce atrial arrhythmias recurrences.The goal of this clinical trial is to evaluate the efficiency of pulsed filed (PF) energy-based bi-atrial modified Maze ablation vs PF energy-based PVI of PeAF.

The main questions it aims to answer are:

Does PF energy effectively perform linear ablation in the left atrium? Does PFA-based bi-atrial modified Maze ablation significantly improve the success rate of PeAF ablation compared with PFA-based PVI?

Patients with PeAF who meet the criteria and undergo catheter ablation will be randomly assigned to the study group (PF-based bi-atrial modified Maze ablation group) and control group (PF-based PVI only) in a 1:1 ratio. All patients will received a 7-d Holter at 3-,6-,9-,12-month after the ablation. The primary endpoint is the freedom from documented atrial arrhythmia (AF/AFL/AT lasting for over 30 seconds) recurrence monitored by ECG, 7-day ambulatory ECG, or equivalent cardiac monitoring from 4th to 12th month after the procedure without taking I/III AADs.

Read the detailed description

Patients with PeAF who meet the criteria and undergo catheter ablation will be randomly assigned to the study group (PF-based bi-atrial modified Maze ablation group) and control group (PF-based PVI only) in a 1:1 ratio. In the study group, patients will receive PF energy based PVI, BOX ablation, LA anterior wall linear ablation from the right superior pulmonary vein to the mitral annulus (under sinus rhythm), MI ablation, linear ablation of the RA posterior wall (up to the superior vena cava and down towards the inferior vena cava according to the potential), and CTI ablation. The patients in the control group will received PVI only with PF energy. If the patients do not restore to sinus rhythm, they will receive electrical cardioversion.

All patients received guideline-directed standardized drug therapy, including anti-arrhythmic medications, postoperatively. Discontinuation of all anti-arrhythmic drugs after the blanking period. All patients will received a 7-d Holter at 3-,6-,9-,12-month after the ablation. The primary endpoint is the freedom from documented atrial arrhythmia (AF/AFL/AT lasting for over 30 seconds) recurrence monitored by ECG, 7-day ambulatory ECG, or equivalent cardiac monitoring from 4th to 12th month after the procedure without taking I/III AADs.

02

Conditions studied

  • Atrial Fibrillation
  • Persistent Atrial Fibrillation

Browse trials for

03

In context

Atrial Fibrillation

4,009 studies on the registry are indexed under Atrial Fibrillation; 961 are open to participants now.

This study's planned enrollment of 390 is above the median of 150 across 2,476 interventional studies indexed under Atrial Fibrillation.

Browse Atrial Fibrillation studies →

Lead sponsor

The First Affiliated Hospital of Dalian Medical University is the lead sponsor of 42 studies on the registry; 10 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with symptomatic PeAF at 18-75 years old who are eligible for the PFA procedure, and have any the following documentation, within 180 days of randomization of either: i. A 24-hour continuous recording (from any regulatory cleared rhythm monitoring device) confirming continuous AF, OR ii. Two ECGs (from any regulatory cleared rhythm monitoring device) showing continuous AF taken at least 7 days,OR iii. physician note of persistent continuous AF for > 7 days
  • The duration of AF lasting ≥ 1 year

Exclusion criteria

Exclusion Criteria:

  • PaAF or PeAF with duration \< 1 year
  • has received catheter ablation procedure for AF or atrial septal defect repair before enrollment
  • left atrial diameter ≥55 mm or thrombosis in the left atrium
  • \<30mL/min/1.73m2
  • a history of cerebrovascular disease within the last three months (including stroke and )
  • acute or severe systemic infection
  • refused to participate in this trial; or those who have participated in other clinical drug trials within 3 months prior to enrollment
  • congenital heart disease, thyroid dysfunction, severe hepatic insufficiency ( classification B-C), severe coagulation dysfunction ( > 1.5 or partial activated prothrombin time prolonged by ≥ 10 seconds, or plasma prothrombin time prolonged by ≥ 3 seconds, or fibrinogen ≤ 1.5 g/L), or active bleeding
  • pregnant women, breastfeeding women or women who plan to become pregnant during the study period, those who have a positive pregnancy test result during the screening period
  • \< 12 months
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
390 participants (estimated)

Study arms

  • Experimental
    PF-based modified Maze ablation

    patients will receive PF energy based PVI, BOX ablation, LA anterior wall linear ablation from the right superior pulmonary vein to the mitral annulus (under sinus rhythm), MI ablation, linear ablation of the RA posterior wall (up to the superior vena cava and down towards the inferior vena cava according to the potential), and CTI ablation.

    Procedure: Modified Maze ablation with PFA

  • Active comparator
    RF-based PVI only

    PVI only with PF energy

    Procedure: PVI only with PFA

Interventions

  • ProcedureModified Maze ablation with PFA

    Modified Maze ablation with PFA

  • ProcedurePVI only with PFA

    PVI only with PFA

06

What researchers measure

Primary outcomes

  1. Freedom from atrial tachycardia during blanking period to Month 12

    freedom of occurrence ≥ 30 sec of Atrial Fibrillation (AF), Atrial Flutter (AFL), atrial Tachycardia (AT); or any electrical cardioversion or re-ablation for AF, AFL, or AT; or any Class I or III AAD use

    Time frame: during blanking period to Month 12

Secondary outcomes

  1. Acute Success - Isolation rate of attempted pulmonary veins and left atrial linear ablation

    Isolation rate of attempted pulmonary veins and left atrial linear ablation

    Time frame: intraprocedure

  2. device or procedure-related Composite Adverse Events

    device or procedure-related Composite Adverse Events including Heart block, Myocardial infarction, Peripheral or organ thromboembolism, Stroke/ Cerebrovascular accident/Transient ischemic attack (TIA),Unresolved phrenic nerve palsy / paresis,Vascular access complications

    Time frame: day 0 to 12 months

  3. procedure time

    procedure time

    Time frame: intraprocedure

07

Study locations

3 sites
  • Jiangsu Provincial Hospital
    Nanjing, Jiangsu 210029, China
    • Fengxiang Zhang · Contact13952037301@139.com · +86 13952037301
    • Fengxiang Zhang · Principal investigator
  • First Affiliated Hospital of Dalian Medical University
    Dalian, Liaoning 116011, China
    • Xiaomeng Yin, Ph.D · Contactdr.yinxm@163.com · +86 18098875778
    • Xiaomeng Yin, Ph.D · Principal investigator
    • Chengming Ma, MD · Sub investigator
    • Yuanjun Sun, MD · Sub investigator
    • Shiyu Dai, MD · Sub investigator
  • The Affiliated Hospital Of Medical School Of Ningbo University
    Ningbo, Zhejiang 315211, China
08

References and documents

Publications

  • Sun Y, Dai S, Xiao X, Wang Z, Yu X, Ma C, Zhang R, Gao L, Xia Y, Yin X. Tailored bi-atrial linear ablation guided by electrophysiological mapping for persistent atrial fibrillation. BMC Cardiovasc Disord. 2024 Nov 20;24(1):658. doi: 10.1186/s12872-024-04332-w. PubMed 39567904 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06952023
Lead sponsor
The First Affiliated Hospital of Dalian Medical University
Responsible party
Sponsor
First posted
Apr 30, 2025
Start date
Jun 2025 (estimated)
Primary completion
May 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Apr 30, 2025

Study contacts

Xiaomeng Yin, Ph.D
Contact
dr.yinxm@163.com
+86 18098875778
Chengming Ma, MD
Contact
machengming@dmu.edu.cn
+86 18098875759

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion